Andrew Binder, MD
Cardiovascular Disease · Plano, TXNPI 1578770707
Payments from drug & device makers
Across 300 payments — averaging $20.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$847
- Heartflow, Inc.$836
- Novo Nordisk$504
- Amgen$481
- Merck$432
- Pfizer$419
- plus $3K from 32 others
What the payments were for
- Food & beverage$6,238100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 45 | $847 |
| Heartflow, Inc. | 14 | $836 |
| Novo Nordisk | 25 | $504 |
| Amgen | 44 | $481 |
| Merck | 21 | $432 |
| Pfizer | 27 | $419 |
| Johnson & Johnson | 16 | $263 |
| Esperion Therapeutics, Inc. | 14 | $225 |
| E.r. Squibb & Sons, L.L.C. | 12 | $215 |
| Medtronic(2 entities) | 4 | $201 |
| AstraZeneca | 9 | $181 |
| Boehringer Ingelheim | 9 | $171 |
| Kiniksa Pharmaceuticals International, PLC | 4 | $145 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 7 | $134 |
| Bayer | 5 | $115 |
| Philips North America LLC | 3 | $101 |
| Boston Scientific | 4 | $100 |
| Inspire Medical Systems, Inc. | 3 | $100 |
| Alnylam Pharmaceuticals Inc. | 3 | $86 |
| Amarin Pharma, Inc. | 4 | $79 |
| Siemens Medical Solutions USA, Inc. | 3 | $64 |
| Impulse Dynamics (USA) Inc. | 1 | $62 |
| Kiniksa Pharmaceuticals, Ltd. | 3 | $59 |
| Itamar Medical Inc | 3 | $53 |
| Bridgebio Pharma, Inc. | 2 | $50 |
| Teleflex LLC | 1 | $50 |
| Cleerly, Inc. | 2 | $41 |
| Cvrx, Inc. | 1 | $38 |
| Sanofi-aventis U.S. LLC | 2 | $35 |
| GSK | 1 | $26 |
| Lexicon Pharmaceuticals, Inc. | 1 | $22 |
| GE HealthCare | 1 | $21 |
| Astellas Pharma US Inc | 1 | $20 |
| Tactile Systems Technology Inc | 1 | $14 |
| Althera Pharmaceuticals LLC | 1 | $13 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
| Lundbeck LLC | 1 | $13 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,238 in reported general payments places this provider in the 60th percentile of 1,515 cardiovascular disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 349 | $463,665 |
| XareltoRivaroxaban | 128 | $159,205 |
| Repatha SureclickEvolocumab | 137 | $155,437 |
| EntrestoSacubitril/Valsartan | 99 | $153,710 |
| JardianceEmpagliflozin | 46 | $58,525 |
| Praluent PenAlirocumab | 46 | $43,054 |
| NexlizetBempedoic Acid/Ezetimibe | 44 | $35,354 |
| FarxigaDapagliflozin Propanediol | 19 | $28,109 |
| Repatha PushtronexEvolocumab | 26 | $20,336 |
| Rosuvastatin Calcium | 859 | $10,606 |
| EdarbiAzilsartan Medoxomil | 17 | $8,627 |
| Metoprolol Succinate | 487 | $7,341 |
| Ezetimibe | 306 | $6,903 |
| Atorvastatin Calcium | 570 | $6,230 |
| Losartan Potassium | 316 | $3,336 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $419 | $463,665349 claims |
| Johnson & JohnsonXarelto | $263 | $159,205128 claims |
| NovartisEntresto | $847 | $153,71099 claims |
| Boehringer IngelheimJardiance | $171 | $58,52546 claims |
| Esperion Therapeutics, Inc.Nexlizet | $225 | $35,35444 claims |
| AstraZenecaFarxiga | $181 | $28,10919 claims |
| Arbor Pharmaceuticals, Inc.Edarbi | $13 | $8,62717 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,515 cardiovascular disease providers in Texas.
Other cardiovascular disease in Plano
- David BrownPlano$2.7M
- Sahil BakshiPlano$628K
- Ramin Farzaneh-FarDallas$17.1M
- Jeffrey GladdenDallas$15.8M
- Ann NavarDallas$14.5M
- David BrabhamAmarillo$11.5M
- Justin GrodinDallas$6.2M
- Christie BallantyneHouston$4.6M
- Syed NaqviHouston$3.6M
- Faisal WahidMcKinney$3.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.